Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Newer chemotherapeutic agents target extracellular signaling, including the mitogen-activated protein kinase kinase (MEK) pathway. We present a case of a 54-year-old female who developed bilateral multifocal central serous-like chorioretinopathy shortly after starting MEK inhibition for metastatic cutaneous melanoma. There was a complete resolution of findings after drug stoppage. After resuming a lower dose of the MEK inhibitor, the findings recurred again but resolved after drug stoppage. Other etiologies were unlikely given the clinical course. The presumed mechanism involves toxicity to the retinal pigment epithelium, with breakdown of the blood-retinal barrier. Recognition of this side effect is important with this new class of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several MEK1/2 inhibitors have been clinically evaluated for cancer therapy, but some of these early-phase trials were stopped prematurely because of toxicity issues, including various ocular adverse effects ( 21 , 68 – 70 ).”
From Loss of Extracellular Signal-Regulated Kinase 1/2 in the Retinal Pigment Epithelium Leads to RPE65 Decrease and Retinal Degeneration (2017) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 1×
“Hindawi Publishing Corporation Case Reports in Ophthalmological Medicine Volume 2013, Article ID 673796, 3 pages http://dx.doi.org/10.1155/2013/673796”
BackgroundInfluentialResistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119
Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L., Ko, M., Aguirre, S., & Younis, H. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0060 · Cited by 90
Jiang (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000191 · Cited by 81
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
Finn, R. S., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D., Anderson, L., Christy-Bittel, J. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.220 · Cited by 48
Acute Onset Central Serous Retinopathy In Association With Mek Inhibitor Use For Metastatic Cancer
Vélez-Montoya, R., Olson, J., Petrash, M. J., Messersmith, W. A., Mandava, N., & Oliver, S. C. N. (2011) · Investigative Ophthalmology & Visual Science · Cited by 13
Cited by
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Francis, J. H., Habib, L. A., Abramson, D. H., Yannuzzi, L. A., Heinemann, M., Gounder, M. M., Grisham, R. N., Postow, M. A., Shoushtari, A. N., Chi, P., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.038 · Cited by 141
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 136
“In a case report on treatment with the MEK inhibitor trametinib, the authors suggested a possible disruption of the pigment epithelial function and, in particular, a loss of barrier functions [21].”
BackgroundOcular toxicities of MEK inhibitors and other targeted therapies
Stjepanovic, N., Velazquez-Martin, J. P., & Bedard, P. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw100 · Cited by 114
Daud, A., & Tsai, K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 94
McCannel, T. A., Chmielowski, B., Finn, R. S., Goldman, J., Ribas, A., Wainberg, Z. A., & McCannel, C. A. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.976 · Cited by 91
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
Duncan, K. E., Chang, L. Y., & Patronas, M. (2015) · Eye · doi:10.1038/eye.2015.82 · Cited by 87
Subretinal Fluid Associated with MEK Inhibitor Use in the Treatment of Systemic Cancer
Weber, M. L., Liang, M. C., Flaherty, K. T., & Heier, J. S. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0090 · Cited by 86
Amer, R., Nalcı, H., & Yalçındağ, F. N. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.05.001 · Cited by 103
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
Draganova, D., Kerger, J., Caspers, L., & Willermain, F. (2015) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-015-0049-9 · Cited by 62
“The occurrence of serous retinal detachments (SRDs), once associated with moderate anterior uveitis, has been reported in Trametinib therapy [7,8].”
BackgroundNeoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 63
Ocular Toxicity of Targeted Anticancer Agents
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2021) · Drugs · doi:10.1007/s40265-021-01507-z · Cited by 64
Niro, A., Strippoli, S., Alessio, G., Sborgia, L., Recchimurzo, N., & Guida, M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.035 · Cited by 45
de la Cruz-Merino, L., Di Guardo, L., Grob, J.-J., Venosa, A., Larkin, J., McArthur, G. A., Ribas, A., Ascierto, P. A., Evans, J. T. R., Gomez-Escobar, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1246-0 · Cited by 44
“Based on the limited scientific literature available, characteristics of serous retinopathy observed with cobimetinib were similar to those of retinal changes observed with other MEK inhibitors [9, 11, 12, 14], suggesting that this is a class effect [11].”
BackgroundRetinal toxicities of systemic anticancer drugs
Arora, S., Surakiatchanukul, T., Arora, T., Errera, M. H., Agrawal, H., Lupidi, M., & Chhablani, J. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.05.007 · Cited by 42
New features in MEK retinopathy
Tyagi, P., & Santiago, C. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0861-8 · Cited by 39
Goodwin, C. B., Li, X.-J., Mali, R., Chan, G., Kang, M. W., Liu, Z.-Y., Vanhaesebroeck, B., Neel, B., Loh, M., Lannutti, B., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535104 · Cited by 39
Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., et al. (2019) · Retina · doi:10.1097/iae.0000000000002027 · Cited by 31
Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy
Parikh, D., Eliott, D., & Kim, L. A. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2778 · Cited by 32
Wide field retinal imaging and the detection of drug associated retinal toxicity
Corradetti, G., Violanti, S. S., Au, A. C., & Sarraf, D. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-019-0172-0 · Cited by 31
“[77] reported that MEK inhibition may induce oxidation and inflammation altering the permeability of the RPE.”
BackgroundImmunogammopathies and Acquired Vitelliform Detachments: A Report of Four Cases
Rusu, I., Mrejen, S., Engelbert, M., Gallego‐Pinazo, R., Ober, M. D., Johnson, M. W., LEYS, A. M., & Yannuzzi, L. A. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.11.020 · Cited by 27
Tan, A. C. S., Yzer, S., Atebara, N. H., Marr, B. P., Verdijk, R. M., Dalm, V. A. S. H., Freund, K. B., Yannuzzi, L. A., & Missotten, T. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.01.017 · Cited by 28
Gavrić, A. U., Ocvirk, J., & Mekjavič, P. J. (2018) · Radiology and Oncology · doi:10.2478/raon-2018-0002 · Cited by 29
Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective
Kanakis, M. G., Petrou, P., Lourida, P., & Georgalas, I. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.05.013 · Cited by 31
Park, Y. J., Kim, Y., Park, K. H., & Woo, S. J. (2019) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20191119-03 · Cited by 25
Booth, A. E. C., Hopkins, A. M., Rowland, A., Kichenadasse, G., Smith, J. R., & Sorich, M. J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920944359 · Cited by 28
Pyakurel, A., Balmer, D., Saba-El-Leil, M. K., Kizilyaprak, C., Daraspe, J., Humbel, B. M., Voisin, L., Le, Y. Z., von Lintig, J., Meloche, S., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00295-17 · Cited by 20
Francis, J. H., Canestraro, J., Haggag-Lindgren, D., Harding, J. J., Diamond, E. L., Drilon, A., Li, B. T., Iyer, G., Schram, A. M., & Abramson, D. H. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.06.001 · Cited by 15
Alves, C., Ribeiro, I., Penedones, A., Mendes, D., & Marques, F. B. (2016) · Ophthalmic Research · doi:10.1159/000446845 · Cited by 18
Giuffré, C., Miserocchi, E., Modorati, G. M., Carnevali, A., Marchese, A., Querques, L., Querques, G., & Bandello, F. M. (2016) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000491 · Cited by 14
Yanagihara, R. T., Tom, E. S., Seitzman, G. D., & Saraf, S. S. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1928714 · Cited by 14
Nolan, D., Lewis, S. A., & Hariprasad, S. M. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160419-01 · Cited by 9
Diagnostic and Therapeutic Challenges
Faure, C., Schwitzer, T., Hansen, C., & Randhawa, S. (2016) · Retina · doi:10.1097/iae.0000000000000988 · Cited by 9
“The differential diagnosis of multiple subretinal hyporeflective areas on OCT with corresponding hypoautofluorescence on autofluorescence imaging includes subretinal fluid blebs after successful retinal detachment surgery,(1) certain variants of vitelliform dystrophy,(2) and multifocal serous detachments seen in patie…”
BackgroundLong-Term Evaluation of MEK Inhibitor Retinal Toxicity With Multimodal Imaging
Sheyman, A. T., Scarinci, F., Fawzi, A. A., & Gill, M. K. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20151214-12 · Cited by 8
Coutu, A., Farguette, F., Jeannin, G., & Chiambaretta, F. (2015) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2015.05.009 · Cited by 8
“Ils décrivent comme pour os patients une atteinte caractérisée à l’OCT et beaucoup oins franche sur les clichés angiographiques [8].”
BackgroundOcular Inflammatory Complications of Treatment for Metastatic Melanoma
Philip, A. M., Anesi, S. D., Foster, C. S., & Chang, P. Y. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2098147 · Cited by 4
Kim, D. H., Xia, T., Bracha, P., & VanderBeek, B. L. (2021) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264211013629 · Cited by 4
“Perturbing the MAPK or MEK pathways with inhibitors such as pimasertib and dabrafenib has been shown to cause bilateral central serous RDs and more rarely bilateral cystoid macular edema.(8,9) It thus follows that perturbing the MAPK pathway upstream through FGFR could have a similar effect.”
BackgroundManiar, R., Gallitano, S. M., Husain, S., Moazami, G., Weiss, M. J., & Shu, C. A. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7084 · Cited by 3
Parikh, D., Patel, V., Yannuzzi, N. A., Greenstein, S. H., Eliott, D., & Kim, L. A. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230501-01 · Cited by 3
Sudden Onset of Multiple Green Spots in the Eyes of a Woman With Breast Cancer
Patel, S. N., & Kim, S. J. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.5288 · Cited by 1
Self-citationOcular Complications of Targeted Therapy
Neiweem, A. E., Jusufbegovic, D., & Singh, A. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-04489-3_14
Der augenärztliche Notfall bei Tumorpatienten
Kakkassery, V., Emmert, S., Rades, D., von Bubnoff, N. C. C., Ranjbar, M., Grisanti, S., Chronopoulos, A., Heindl, L. M., & Adamietz, I. U. A. (2020) · Der Onkologe · doi:10.1007/s00761-019-00694-5
Friends or Foes? An Update on Retinal Toxicities of Systemic Medications
Zhang, R., Hariprasad, S. M., Sanchez, G., & Mantopoulos, D. (2021) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20210528-01
Patel, G., Edirisooriya, M., Dey, M., & Parkar, R. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100208 · Cited by 2
Drugs Causing Uveitis: Pathogenesis, Diagnosis and Treatment
Yıldız, M., AVCI, R., & YILMAZ, S. (2023) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0341
Rastoaca, C., Berger, T., Seitz, B., & Abdin, A. D. (2024) · Die Ophthalmologie · doi:10.1007/s00347-024-02140-3
Metadata
- Authors
- Schoenberger, S. D., & Kim, S. J.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Kim, Stephen J.
- ORCID
- Kim, Stephen J.
- Venue
- Case Reports in Ophthalmological Medicine
- Publisher
- Hindawi Limited
- Published
- 2013
- Volume
- 2013
- Pages
- 1-3
- ISSN
- 2090-6722 (ISSN-L)
- 2090-6730
- PMC
- PMC3608121
- OpenAlex
- W2054319863
- Cited by
- 46
- References
- 6
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 4 · 2014: 3 · 2013: 1
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Case Reports in Ophthalmological Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Research to Prevent Blindness
- Vanderbilt University
- School of Medicine, Vanderbilt University
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- MEK inhibitors, metastatic cutaneous melanoma, drug-induced retinal toxicity, retinal pigment epithelium, blood-retinal barrier breakdown, MAPK signaling, adverse drug reactions, chemotherapy side effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.